Real-World Use and Outcomes of Olaparib: a Population-Based Cohort Study

Abstract P3-17-03: Concordance of real world progression free survival (PFS) on endocrine therapy as first line treatment for metastatic breast cancer using electronic health record with proper quality control versus conventional PFS from a phase 3 trial

(2018) CH Bartlett et al.   CANCER RESEARCH

First PARP Inhibitor Ok'd for Breast Cancer

(2018)   Cancer Discovery

Olaparib in German routine clinical practice: Updated interim results of the non-interventional study C-PATROL.

(2018) Frederik Marme et al.   JOURNAL OF CLINICAL ONCOLOGY

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

(2018) Kathleen Moore et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Swedish cause of death register

(2017) Hannah Louise Brooke et al.   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Real-world Data for Clinical Evidence Generation in Oncology

(2017) Sean Khozin et al.   JNCI-Journal of the National Cancer Institute

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

(2017) Eric Pujade-Lauraine et al.   LANCET ONCOLOGY

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

(2017) Mark Robson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Real-world Data for Clinical Evidence Generation in Oncology

(2017) Sean Khozin et al.   JNCI-Journal of the National Cancer Institute

PARP inhibitors as precision medicine for cancer treatment

(2017) Yi Du et al.   National Science Review

The First Decade with the Swedish Prescribed Drug Register - A Systematic Review of the Output in the Scientific Literature

(2016) Susanna M. Wallerstedt et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Opportunities and challenges in leveraging electronic health record data in oncology

(2016) Marc L Berger et al.   Future Oncology

Healthcare Utilisation and Drug Treatment in a Large Cohort of Patients with Inflammatory Bowel Disease

(2016) Thomas Cars et al.   Journal of Crohns & Colitis

DNA repair targeted therapy: The past or future of cancer treatment?

(2016) Navnath S. Gavande et al.   PHARMACOLOGY & THERAPEUTICS

Olaparib: First Global Approval

(2015) Emma D. Deeks   DRUGS

2755 First real life data on Olaparib in BRCA1/2 mutated Platinum-Sensitive Relapsed (PSR) Epithelial Ovarian Cancer (EOC) in France: Analysis of 52 patients (pts) enrolled in the French Temporary Authorization for Use (ATU)

(2015) T. De La Motte Rouge et al.   EUROPEAN JOURNAL OF CANCER

19th International Meeting of the European Society of Gynecological Oncology (ESGO 2015)

(2015)   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Challenges in economic modeling of anticancer therapies: an example of modeling the survival benefit of olaparib maintenance therapy for patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer

(2015) Robert Hettle et al.   JOURNAL OF MEDICAL ECONOMICS

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

(2014) Jonathan Ledermann et al.   LANCET ONCOLOGY

Bringing in health technology assessment and cost-effectiveness considerations at an early stage of drug development

(2014) Bengt Jönsson   Molecular Oncology

Extraction of Electronic Health Record Data in a Hospital Setting: Comparison of Automatic and Semi-Automatic Methods Using Anti-TNF Therapy as Model

(2013) Thomas Cars et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

External review and validation of the Swedish national inpatient register

(2011) Jonas F Ludvigsson et al.   BMC PUBLIC HEALTH

The completeness of the Swedish Cancer Register – a sample survey for year 1998

(2008) Lotti Barlow et al.   ACTA ONCOLOGICA